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Summary A total of 1664 patients with gastric cancer were examined to evaluate the rate of multiple synchronous primary tumours. In cases
of multiple synchronous cancer (MSC), the tumours were analysed immunohistochemically for their expression pattern of p53, c-erbB2, ras,
E-cadherin and proliferative activity. Multiple synchronous gastric carcinomas (MSCs) were observed in 61 out of 1664 patients (3.7%), with
a total of 134 carcinomas. In our series, early carcinoma was observed more frequently in MSC than in solitary cancers. The comparison of
tumour stage in MSC and solitary tumours revealed that multiple early gastric cancers were significantly more often of type I (protruded type)
and Ila (superficial elevated type) than solitary early cancer. Multiple advanced carcinomas were more often of a lower pT category than
solitary advanced gastric cancer. Performing immunohistochemistry for p53, c-erbB2 and ras in 134 tumours with MSCs, we observed
positivity rates of 33%, 59% and 87% respectively. In 43 patients, the multiple tumours in each individual patient demonstrated an identical
status of p53 and c-erbB2, and in 42 patients a similar pattern of E-cadherin expression was observed. The proliferative index, determined by
proliferating cell nuclear antigen (PCNA) immunolabelling, did not differ significantly between the MSC in each patient. Ras immunostaining
was detected in 53 out of 61 patients, but also in metaplasia and regenerative hyperplasia in the specimens. In survival analysis, no difference
was observed between patients with solitary or multiple early or advanced carcinomas. Our results suggest that in at least a high proportion
of patients with gastric cancer multiple primary tumours arise from precancerous conditions leading to similargenetic alterations.
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The synchronous occurrence of more than one primary tumour in
the stomach is well recognized and has been attributed to the
concept of 'field carcinogenesis', which is based on the hypothesis
of independent transformation of multiple epithelial cells at
several sites owing to prolonged exposure to carcinogens. An
alternative theory is based on the premise that any transforming
event is rare; after initial transformation, the progeny of the
transformed clone spread through the mucosa and give rise to
geographically distinct but genetically related synchronous
tumours. The terminology of 'synchronous' carcinomas remains
confused. In the literature, cases are variously designated as
multiple, multiple synchronous, multiple simultaneous, multi-
centric or multifocal carcinomas. Some authors consider only
multiple grossly detected tumours; others also include single
grossly detected tumours associated with separate microscopic
foci. Further differences in definitions arise in cases in which
primary diagnosis of a single cancer is followed by the diagnosis
of another cancer within a few months. Such cases are sometimes
considered synchronous, at other times metachronous.
For this study, we used the criteria of Moertel (1957) for the
definition ofmultiplicity. He required that: (a) each lesion must be
of pathologically proven malignancy; (b) the tumours must be
separated by each other by intervals of microscopically normal
gastric wall; and (c) the possibility that one of the lesions repre-
sents a local extension or a metastatic tumour must be ruled out
beyond any reasonable doubt. The present examination is based on
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a large study of gastric cancer patients all of whom were docu-




Data were obtained from the Erlangen Cancer Center (ECC) on
1664 patients with stomach cancer who had been treated with
resective surgery between 1969 and 1988. In defining multiple
simultaneous cancers multiple synchronous gastric carcinomas
(MSC), the recommendations of the UICC (TNM Supplement
1993) and ofMoertel (1957, 1966) were used.
Out of 1664 patients with gastric cancer, 65 had MSC (3.9%)
and 1599 had solitary cancers. Four of these patients had solitary
carcinomas as well as other malignant gastric tumours (three
non-Hodgkin's lymphomas, one leiomyosarcoma). Patients with
gastric tumours other than epithelial carcinomas were excluded
from immunhistochemical analysis.
Out of 61 patients with a total of 134 carcinomas, 53 had two
carcinomas, four patients had three carcinomas, one patient had
two carcinomas and a malignant non-Hodgkin's lymphoma, two
patients had four carcinomas and one patient had six carcinomas.
Analysed data
MSC cases were analysed with respect to age, sex, type of opera-
tion performed, localization (site) (classification according to
Hermanek, 1986), macroscopic type (Borrinann classification,
classification of early gastric cancer according to the rules of the
Japanese Research Society for Gastric Cancer, 1982), histological
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Table 1 Antibodies used for immunhistochemistry
Antibody (clone) Source Dilution
PCNA (PC10) Oncogene Science, Uniondale, NY, USA 1:500
p53 (DO-7) DAKO Diagnostics, Denmark 1:50
c-erbB2 (CB11) BioGenex, Hamburg, Germany 1:80
E-cadherin (DECMA-1) SIGMA-Biochemicals, St. Louis, MO, USA 1:200
ras (F132-62) Boehringer Mannheim, Germany 1:80
Table 2 Comparison of patient data for solitary and multiple gastric tumours
(n= 1644)
Patient data Solitary tumour Multiple tumours
(n= 1599) (n=65)
Median age 61.8 years 67.7 years NS
Male sex 1040 (65%) 45 (69%) NS
Total gastrectomy 763 (48%) 36 (55%) NS
EGC (pTl) only 251 (16%) 15 (23%) NS
pN1/pN2 1035 (65%) 35 (54%) NS
(p) Ml 281 (18%) 8 (12%) NS
NS, not significant.
Table 3 Incidence, depth of invasion and macroscopic classification of EGC
in solitary and multiple gastric carcinomas (n = 1733)
Tumour data Solitary Multiple Statistical
(n = 1599) (n = 134) differences
Early cancer 251 (15.7%) 72 (54%) P< 0.001
Mucosa 119 (47%) 28 (39%)
Submucosa 132 (53%) 44 (61%) NS
53 (21%) 29 (40%)
Ila 12 (5%) 10 (14%)
llb 13 (5%) 4 (6%)
Ilc 110 (44%) 25 (35%) P< 0.001
III 24 (10%) 2 (3%)
Combined 39 (16%) 2 (3%)
NS, not significant
Table 4 Tumour localization and multiplicity of gastric carcinomas
(n = 1733)
Involvement of Solitary Multiple Statistical
thirds (n = 1599) (n = 134) differences
Only one 1171 (73%) 123 (92%) P < 0.001
Upper-third site 479 (41%) 39 (32%)
Middle-third site 242 (21%) 35 (28%) NS
Lower-third site 450 (39%) 49 (40%)
Two or three 428 (27%) 11 (8%) P < 0.001
type according to WHO (1990), (including conventional classifi-
cation and Lauren classification, 1965), histological grade
(WHO), pTNM stage (UICC 1987; 1992), status of tumour-free
mucosa, presence ofresidues ofadenomas at the margins ofcarci-
noma and accompanying adenomas.
Pathological examination
The unfixed resection specimens were opened and examined
macroscopically by the pathologist, with special emphasis on the
margins ofclearance. After fixation with 10% formalin, specimens
were once again macroscopically examined and multiple blocks
were taken from the tumour, from the mucosa of the antrum and
from the corpus distant to the tumour, and from additional
macroscopically suspicious lesions. Furthermore, cut sections
were taken from the proximal, distal and lateral resection margins.
The surgeon generally removed the lymph drainage area along
with the tumour.
After separation of the different lymph node groups according
to the Japanese general rules (1982), and further separation of the
node groups 1-6 into nodes within 3 cm and those more than 3 cm
from the edge of the primary tumour, the nodes were carefully
grossly dissected. All nodes as well as all structures with suspi-
cious lymph nodes were embedded for histology.
Immunohistochemical analysis
For immunohistochemical analysis, p53, c-erbB2, ras and E-
cadherin were selected because these markers have been reported
to play a major role in gastric carcinogenesis and are mutated or
overexpressed in ahigh numberofcases. Moreover, because ofthe
availability of monoclonal antibodies, the examination of these
molecules is feasible in a large series of paraffin-embedded
specimens.
Immunostaining for p53, c-erbB2, ras and E-cadherin and also
PCNA (proliferating cell nuclear antigen) was performed by
applying the labelled aridin biotin (LAB) method, as described
previously, on paraffin sections (Tannapfel et al, 1996a). After
dewaxing and rehydration, endogenous peroxidase activity was
blocked by 3% hydrogen peroxide in methanol for 30 min. The
prepared sections were covered with normal goat serum for20 min
and then incubated with the primary antibodies (see Table 1). Then
the sections were washed with phosphate-buffered saline, incu-
bated with biotinylated second antibody for 30 min and covered
with peroxidase-conjugated streptavidin (Dakopatts, Denmark).
The peroxidase reaction was allowed to proceed for 8 min, with
0.05% 3,3-diaminobenzidine tetrahydrochloride solution as
substrate. Slides were counterstained with haematoxylin, dehy-
drated in a series ofgraded alcohols and finally mounted.
Sections known to stain positively were included in each batch
and negative controls were also performed by replacing the
primary antibody with goat ascites fluid (Sigma-Aldrich
Biochemicals, St. Louis, MO, USA).
Two sections from two different paraffin-embedded tumour
tissue blocks were examined and scored independently by two of
us in the absence of any clinical or pathological information. The
positivity of the markers was assessed by counting an average
number of 800 tumour cells, in sections of 200 cells each in four
different fields ofevery tumour. Two slides were counted in every
case, leading to a total of 1600 evaluated tumour cells for each
carcinoma. An eyepiece integration grid was used to ensure that
cells were evaluated only once. Stained tumour cells were identi-
fied as positive using a light microscope (magnified 400 times).
The PCNA index and also the positivity for p53 was calculated
as the percentage ofcells with positive nuclear staining in the total
number of tumour cells counted (Tannapfel et al, 1996b). The
intra-observer error was calculated in a preliminary examination
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using the same material; we found that at least 130 tumour cell
nuclei needed to be assessed for the results to fall within 5% ofthe
estimated real mean with a probability of95%.
To minimize inter-observer error, all counts were performed
separately. In three cases in which conflicting numbers ofpositive
cells were evaluated, recounting was performed to obtain a
concordance ofopinion.
As in previous studies (Gabbert et al, 1996; Tannapfel et al,
1994), the E-cadherin expression was evaluated semiquantitatively
and scored in one ofthe following categories: +++, linearordotted
intercellular staining pattern preserved similar to that of normal
gastric epithelium in more than 60% of the tumour cells; ++,
moderately reduced linear or dotted intercellular staining in
20-60% ofall tumour cells; +, highly reduced, finely dotted inter-
cellular staining in less than 20% ofall tumourcells; -, no staining
or very weak E-cadherin expression in less than 5% of all tumour
cells. The staining intensity by itself was not relevant in the
scoring system.
Statistical methods
Differences in frequencies were tested for significance by the chi-
square test and, if appropriate, with the Yates' correction or by
Fisher's exact test. Survival rates were calculated by actuarial
method; surgical mortality was not excluded. The twofold
standard errors corresponding to the 95% confidence interval
were added to the observed and relative (age-corrected) rates.
Differences in survival were tested by the z-test.
RESULTS
Pathohistological data
MSCs were observed in 61 out of 1664 patients (3.7%). Data on
age, sex, type of resective surgery and pTNM are shown in Table
2. The rate of lymph node metastasis and distant metastasis was
somewhat lower in patients with multiple cancer, but this differ-
ence was not significant (Table 2). Early carcinomas (EGC)
were observed more frequently in MSCs than in solitary cancers
(P < 0.001) (Table 3).
Furthermore, multiple EGCs were significantly more often of
type I and hIa than solitary EGC (Table 3). MSCs significantly
more often involved only one-third ofthe stomach, however, there
was no difference between multiple and solitary cancer in relation
to localization (Table 4). Multiple advanced carcinomas were
significantly more often in a lower pT category than solitary
advanced gastric carcinoma (AGC) (Table 5). The distribution of
the Lauren classification in patients with MSCs is shown in Table
6. MSCs exhibited significantly more often a low grade of histo-
logical differentiation (GI, G2) than solitary carcinomas (Table 7).
In cases with multiple tumours, we found a significantly higher
number of associated adenomas, atrophic gastritis and intestinal
metaplasia than solitary cancers (Table 8). In patients with a
history of previous distal gastrectomy, the incidence of multiple
advanced carcinomas was identical to that of non-resected
patients: 2 out of61 (3%) vs 43 out of 1337 (3.5%). However, the
incidence of EGCs was significantly higher in patients with
previous surgery: 4 out of 21 (19%) vs 11 out of 245 (4.5%)
(P < 0.05). In survival analysis, no difference was observed
between patients with solitary or multiple early or advanced carci-
nomas (Table 9).
Table 5 Borrmann classification (pT category) and multiplicity of advanced
gastric carcinoma (AGC)
Borrmann type Solitary AGC Multiple AGC Statistical
(n = 1348) (n= 62) difference
123 (9%) 20 (32%)
11 346 (26%) 19 (31%)
III 469 (35%) 14 (23%) P< 0.001
IV 348 (26%) 5 (8%)
Unclassified 62 (5%) 4 (6%)
pT category
pT2 709 (53%) 47 (76%)
pT3 517 (38%) 12 (19%) P< 0.01
pT4 121 (10%) 2 (3%)
pTx 1 1 (2%)
Table 6 Distribution of Laur6n classification in multiple gastric carcinomas
Patients n = 61
Intestinal type only 34
Diffuse type only 10
Diffuse and intestinal type 16
Intestinal type and unclassified 1
Carcinomas n= 134
Intestinal type only 97
Diffuse type only 36
Unclassified 1
Table 7 Histological grade and multiplicity of gastric carcinoma
Solitary Multiple Statistical
(n= 1599) (n = 134) difference
Laur6n type
Intestinal 747 (47%) 97 (72%)
Diffuse 756 (47%) 36 (27%) P < 0.001
Unclassified 96 (6%) 1
Grade
Gl 167 (10%) 27 (20%)
G2 239 (15%) 38 (28%)
G3 679 (43%) 51 (38%) P< 0.001
G4 403 (25%) 18 (14%)
ungraded 111 (7%) -





(n = 1599) (n =61)
Residual adenoma demonstrable 39 (2%) 3 (5%) NS
Associated adenoma 38 (2%) 6 (10%) P< 0.05
Atrophic gastritis or atrophy 257 (16%) 17 (28%) P< 0.05
Intestinal metaplasia 680 (43%) 38 (62%) P< 0.025
Immunohistochemical analysis
PCNApositivity was foundin the nuclei ofall cases ofgastric carci-
nomas in amounts that varied from case to case. The percentage of
PCNA positivity ranged from 1% to 89%, with a median of 39%.
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Table 9 Survival rates in patients with solitary and multiple gastric tumours
n ± 5-year survival rate % Median survival
(± two-fold standard error [95% Cl]) time (months)
Observed Age corrected
AGS
Solitary 1348 24 (± 2) 29 (± 3) 15.6
Multiple 50 24 13) 31 (±17) 11.7
EGC
Solitary 251 66 (± 7) 79 (± 8) Undefined
Multiple 15 66 (± 25) 87 (± 32) Undefined
Table 10 Immunohistochemical findings for PCNA, p53 and c-erbB2 in the 134 MSCs
PCNA p53 c-erbB2
Median SD Range
97 intestinal types 22 12.5 2-59* 40/97 (41%) 78/97 (80%)*
36 diffuse types 54 22.3 1-89* 3/36 (8%) 1/36 (3%)*
Unclassified 63 1/1 (100%) 0/1
134 Carcinomas 39 20.7 1-89 44/134 (33%) 79/134 (59%)
*Significant differences of P < 0.05.
Table 11 E-cadherin expression and histological type in the MSCs
Expression of E-cadherin
Statistical +++ + | + NegativeStisca difference
Lauren type
Intestinal 35/97 (36%) 44/97 (45%) 12/97 (12%) 6/97 (6%)
Diffuse 1/36 (3%) 1/36 (3%) 8/36 (22%) 26/36 (72%) P< 0.05
Unclassified - - - 1/1
Total 36/134 (27%) 45/134 (34%) 20/134 (15%) 33/134 (25%)
Normal gastric tissue exhibited apositivity for PCNA to 15%. There
was a significant correlation between PCNA indices andhistological
grade, rising towards higher indices in poorly differentiated tumours
and in the diffuse type (according to Lauren) (P < 0.05) (Table 10).
Positive staining for p53 was seen in 44 out of 134 tumours
(33%). The p53 immunoreactivity was confined to the tumour cell
nuclei, but sometimes additional very faint cytoplasmic staining
was observed. Normal gastric epithelium was always negative for
p53 in intestinal metaplasia and also in adenoma, and we could
detect few positive cell nuclei (less than 10% in every case). For
c-erbB2, an immunoreactivity confined to the basolateral tumour
cell membrane was observed in 79 out of 134 tumours (59%). In
intestinal type gastric cancer, we could detect c-erbB2 signifi-
cantly more often than in diffuse type (P < 0.05) (see Table 10).
Ras immunostaining was detected in 117 out of 134 cases. In addi-
tion, we found intracytoplasmic positivity for ras in intestinal
metaplasia, regenerative hyperplasia and also occasionally in
normal epithelium.
E-cadherin immunoreactivity could be detected as positive
staining of varying intensity in the tumour cell membrane in 101
out of 134 carcinomas (75%). With respect to growth pattern,
E-cadherin was significantly more often preserved in intestinal-
type carcinomas ofLauren than in diffuse-type carcinomas (Table
11). An inverse correlation was shown between E-cadherin
expression and grade of tumour differentiation. The majority of
well or moderately (GI, G2) tumours belonged to tumours with a
preserved (scored as +++ or ++) E-cadherin expression.
When comparing each tumour ofan invidual patient with MSC,
we could find an identical status ofp53 and for c-erbB2 in 43 out
of 61 patients. A similar pattern of E-cadherin expression was
observed in 42 out of 61 patients. In MSCs with differences in the
histological grade of tumour differentiation or Lauren classifica-
tion among the tumours, we found differences in p53 and c-erbB2
expression. In 17 cases, in which the MSCs were ofdifferent histo-
logical grade of differentiation and Lauren classification, differ-
ences in c-erbB2, p53 and also E-cadherin were observed. This is
largely owing to the fact that we failed to detect c-erbB2 and p53
in significant amounts in diffuse types ofgastric cancer (Table 10).
In the patient with six MSCs, two lesions were positive for p53
and one for c-erbB2.
The PCNA-index was not significantly different between the
MSCs ofeach patient. We failed to detect any statistical differences
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in positivity for p53, c-erbB2, ras or E-cadherin in relation to
tumour stage or between the expression ofthese markers and early
or advanced gastric cancer.
DISCUSSION
There have been many papers dealing with the problem of simulta-
neous multiplicity ofgastric cancers. However, as arule, the authors
have covered only some aspects, i.e. macroscopic appearance,
histology or multiplicity in early gastric cancer (Konjetzny, 1938,
Albrecht, 1952, Moertel et al, 1957, Johanson, 1976, Marrano et al,
1987, Honmyo et al, 1989, Kodera et al, 1995). We thus felt it
necessary to publish our data on gastric cancerpatients which, have
been collected in a standardized way, including data on accompa-
nying precancerous lesions and present additional data on expres-
sion of various tumour-associated genetic changes. Our rate of
multiplicity of 3.7% is similar to that found by Rohde et al (1991)
and Mitsudomi et al (1989). A clinical study by Kodera et al (1995)
of 2790 patients reported MSCs in 160 cases (5.7%). Accordingly,
the question arises whethermultifocality indicates theexistenceofa
specific 'organ or tissue susceptibility' to neoplasms. Whereas we
found no significant differences between solitary and multiple
gastric cancers in relation to median age, sex, pN category, presence
of distant metastases at the time of diagnosis or survival rates, an
identical expression status ofp53, c-erbB2, ras and also E-cadherin
has been found in MSCs in a high percentage of cases. In most of
these patients, in whom a different expression pattern of p53 or
c-erbB2 and PCNA was observed, the synchronous lesions were of
adifferent grade ofdifferentiation orLauren classification (Hall and
Levinson, 1990; Hall and Woods, 1990; Shioa et al, 1994).
Ourdata ofpositivity rates of33% forp53 and 59% for c-erbB2
are similar to the rates found in solitary gastric carcinomas, as
reported previously (Yonemura et al, 1991; Jiihne et al, 1994,
Shioa et al, 1994; Stemmermann et al, 1994; Imatani et al, 1996).
In agreement with Gabbert et al (1996), who examined solitary
gastric carcinomas, we found a significant correlation between the
intensity ofE-cadherin expression and the grade oftumour differ-
entiation as well as histological type according to the Lauren clas-
sification. The focal expression of the ras oncoprotein in
regenerative epithelium as well as in intestinal metaplasia and
adenomas is a well-known characteristic in solitary carcinomas
and adjacent mucosa, and seemingly not specific for gastric
epithelium in MSCs patients (Czerniak et al, 1989; Wright and
Williams, 1993).
Thus, from ourresults and those ofothers, it seems reasonable to
conclude that in a significant number of cases, multiple gastric
carcinomas do arise as the result of the progressive growth and
coalescence of multiple, smaller neighbouring tumours with iden-
tical genetic alterations (Kodera et al, 1995; Shinmura et al, 1995;
Ito et al, 1997). Heterogeneity in tumour differentiation within the
same tumourmay be due tothe subsequent genetic instability ofthe
original cancerous clone, but also occurs secondary to the effect of
environmental factors on cancer cells during the evolution of the
cancer disease (Aretxabala et al, 1988; Tannapfel et al, 1994).
In our series, MSCs were significantly more often early carci-
nomas. In agreement with Bearzi and Ranaldi (1986), we found
that multiple EGCs significantly more often displayed type I and
IIa ofthe Japanese classification ofEGC.
The comparison of solitary carcinomas and patients with MSCs
revealed that the latter significantly more often showed intestinal
type of Lauren classification, which roughly corresponds to the
well- and moderately differentiated carcinomas of papillary, tubu-
lary and mucinous type in the conventional classification. These
types were significantly more frequently observed in multiple
carcinomas. Bearzi and Ranaldi (1986) felt that the differences
between multifocal and solitary early gastric cancer did not
necessarily reflect distinctbiological behaviours but may represent
different stages of the same neoplastic process and thus be a
consequence of different intervals between onset and diagnosis.
Similarly, our data indicate that multiple and solitary carcinomas
represent different developmental stages of a primarily identical
process, the phenotype being dependent on speed of progression:
slow progression results in multiple tumours andrapidprogression
in solitary tumours. Compared with accompanying and precan-
cerous lesions, multiple carcinomas were significantly more often
associated with adenomas, atrophic gastritis or intestinal meta-
plasia than with solitary carcinomas in our series. We thus
conclude that multiple carcinomas more frequently occur in 'field
changes', i.e. diffuse precancerous conditions.
The incidence ofMSCs is not only a phenomenon that is inter-
esting from a theoretical point of view, but also important in
clinical practice. It must be emphasized that MSCs are not always
diagnosed in routine gastroscopy before surgery (Honmyo et al,
1989), in particular small early cancers of macroscopic type Ilb
(Ikeda et al, 1995). Therefore, ifa subtotal gastrectomy is planned,
a second meticulous preoperative gastroscopy could be helpful.
However, the surgeon should examine the gastric remnant care-
fully during the operation to minimize the danger of another
cancerremaining in the gastric stump.
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